Lantheus stock trades at USD 99.72 after FDA approval

Published on 09/25/2026 at 13:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lantheus stock carries a USD 102.50 cash offer plus a CVR of up to USD 12.00 per share from August 3, 2026. FDA approved BRAVNETSA on September 22, 2026.

LANT, US5156731020, Illustration mit AI erstellt.

Lantheus Holdings (ISIN US5156731020) stock was quoted at USD 99.72 on Nasdaq on September 24, 2026, with a daily change of -0.25 percent. On September 22, 2026, GlobeNewswire reported that the FDA granted final approval for BRAVNETSA, a lutetium Lu 177 dotatate treatment for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

FDA approval expands oncology portfolio

BRAVNETSA was approved through the Abbreviated New Drug Application pathway. The FDA determined that the product is bioequivalent and therapeutically equivalent to LUTATHERA, giving Lantheus an approved radiopharmaceutical for foregut, midgut, and hindgut neuroendocrine tumors, according to GlobeNewswire.

The approval adds an oncology product while the company remains tied to a pending transaction. The release describes BRAVNETSA as the first radioligand therapy approved through the ANDA pathway, but it does not set a launch date.

Merger value anchors the share price

Under the Curium agreement, shareholders would receive USD 102.50 in cash plus a non-transferable contingent value right worth up to USD 12.00 per share. The transaction could reach USD 114.50 per share and has a potential value of USD 8.0 billion, according to StockTitan.

Curium resubmitted its Hart-Scott-Rodino filing on September 21, 2026, starting a 30-day waiting period that runs to October 21, 2026. The deal is expected to close in the first half of 2027, subject to regulatory and shareholder approvals.

Revenue grows while PYLARIFY declines

For the quarter ended June 30, 2026, Lantheus reported worldwide revenue of USD 388.18 million, up 2.7 percent from the prior-year quarter. GAAP diluted EPS was USD 1.11 versus USD 1.12 a year earlier, while adjusted diluted EPS was USD 1.55 versus USD 1.57, according to StockTitan.

Product trends were uneven: PYLARIFY sales fell 4.1 percent to USD 240.4 million, while DEFINITY sales rose 5.2 percent to USD 88.3 million. MarketBeat lists a consensus Hold rating and an average 12-month price target of USD 108.11, placing the target 8.42 percent above the September 24 quote, according to MarketBeat.

Stock remains below yearly high

The latest Nasdaq quote of USD 99.72 was 10.85 percent below the 52-week high of USD 111.86 and above the 52-week low of USD 49.67. Market capitalization stood at USD 6,492,378,497, and volume was 938,537 shares on September 24, 2026.